Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why
Though Amgen reported encouraging results on two immunology drugs, Wall Street expresses skepticism as the data fell short ...
Amgen stock slides 5% as analysts weigh in on drug study results (update)
Amgen (NASDAQ:AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs ...
Amgen’s stock falls 4% as analysts say drug updates lag competitors
The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...
Amgen Stock Falls on Disappointing Drug Data
Amgen shares fell 4.5% after the biotech revealed disappointing study results for two closely watched drug candidates. The company, in a call with analysts and investors, reported positiv ...
FiercePharma2d
With success in myasthenia gravis trial, Amgen's Uplizna looks set up to add new indication
As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...
Amgen slips on eczema drug results
Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results ...
Neutral Hold on Amgen: Balancing Uplizna’s Market Potential Against Rocatinlimab’s Competitive Challenges
Bank of America Securities analyst Charlie CY Yang has maintained their neutral stance on AMGN stock, giving a Hold rating today. Charlie CY ...
BioSpace2d
Amgen Scores Late-Stage Wins in Eczema and Myasthenia Gravis, But Analysts See Mixed Results
Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...
Amgen claims success for two immune drugs, but results underwhelm Wall Street
Medicines the company is developing for eczema and myasthenia gravis met their objectives in Phase 3 trials. But analysts ...